What's fueling the biotech engine—2007

  • An Erratum to this article was published on 01 February 2009
  • A Corrigendum to this article was published on 01 February 2009

Despite losses in revenue from erythropoietins, historically the highest earner of all biologics, more than 100 biotech drugs continued their upward trend in sales begun in 2006, with antibodies and insulin analogs fueling growth at double-digit rates.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1
Figure 2: Top 11 companies that comprise the majority of sales of biologic drugs in 2007.
Figure 3: Top ten categories of biologic drugs in terms of US sales in 2007.
Figure 4: Trends in US sales of mAbs.
Figure 5: Trends in US sales of growth factors.
Figure 6: Trends in US sales of recombinant hormones.
Figure 7: US sales of recombinant cytokines and recombinant vaccines.
Figure 8: US sales of blood factors, therapeutic enzymes and anti-coagulants.

Change history

  • 09 February 2009

    In the version of this article initially published, 2007 US sales of therapeutic enzymes in Figure 3 were incorrectly listed as $0.7 billion. They should be $0.9 billion. In the same figure, the 2007 growth (%) was incorrectly listed as –14%; it should be 18%. On page 1230, human growth hormone sales growth rate was incorrectly reported as 45%; it should be 5%. The errors have been corrected in the PDF and HTML versions of this article.

  • 09 February 2009

    In the version of this article initially published, in Figure 5, the $2.40 billion pie section was mislabeled as Rituxan. It should be Procrit. The error has been corrected in the PDF and HTML versions of this article.

References

  1. 1

    Long, D., US Pharmaceutical Market: Trends, Issues, Outlook, IMS Health, Norwalk, CT, USA (April 8, 2008).

  2. 2

    Aggarwal, S. Nat. Biotechnol. 25, 1097–1104 (2007).

    CAS  Article  Google Scholar 

  3. 3

    Ricklin, D. & Lambris, J.D. Nat. Biotechnol. 25, 1265–1275 (2007).

    CAS  Article  Google Scholar 

  4. 4

    Steinbrook, R. N. Engl. J. Med. 356, 2448–2451 (2007).

    CAS  Article  Google Scholar 

  5. 5

    Schneider, C.K. & Kalinke, U. Nat. Biotechnol. 26, 985–990 (2008).

    CAS  Article  Google Scholar 

  6. 6

    Mack, G.S. Nat. Biotechnol. 25, 1331–1332 (2007).

    CAS  Article  Google Scholar 

  7. 7

    Ratner, M. Nat. Biotechnol. 26, 485 (2008).

    CAS  Article  Google Scholar 

  8. 8

    Kuter, D.J. Eur. J. Haematol. Suppl. 69, 9–18 (2008).

    CAS  Article  Google Scholar 

  9. 9

    Johnston, M.I. & Fauci, A.S. N. Engl. J. Med. 359, 888–890 (2008).

    CAS  Article  Google Scholar 

  10. 10

    Kim, J.J. & Goldie, S.J. N. Engl. J. Med. 359, 821–832 (2008).

    CAS  Article  Google Scholar 

  11. 11

    Lanthier, M, Behrman, R, and Nardinelli, C., Economic issues with follow-on protein products Nature Reviews Drug Discovery, 7, 733–737 (2008).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Aggarwal, S. What's fueling the biotech engine—2007. Nat Biotechnol 26, 1227–1233 (2008). https://doi.org/10.1038/nbt1108-1227

Download citation

Further reading